A survey has shown what 389 patient groups think of the 33 leading pharma companies in the cancer space.
Their views are detailed in a report entitled The Corporate Reputation of Pharma - from the Perspective of Cancer Patient Groups.
The 2019 results are drawn from a survey of cancer patient groups from 57 countries, conducted between November 2019 and February 2020.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze